Navigation Links
Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
Date:10/31/2013

BEIJING, Oct. 31, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:  SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Weidong Yin, Chairman, President and CEO of Sinovac, is invited to participate in UBS Asia Healthcare CEO Summit held in Hong Kong on November 1, 2013. And Mr. Yin will join the panel discussion from 4:00 pm to 5:00 pm Beijing time, talking about Chinese healthcare industry and new product development strategy.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and mumps, as well as animal rabies vaccine for canines. The Company recently concluded the phase III clinical trial for enterovirus 71 (against hand, foot and mouth disease) and filed new drug application with China Food & Drug Administration. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee

Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel:  +1-646-536-7028
Email: aestrada@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
2. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. ViroPharma to Participate in Two December Healthcare Investor Conferences
5. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
6. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
7. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
8. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
9. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
10. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
11. AVANIR Pharmaceuticals To participate in two conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a ... downlights designed to stay tightly sealed and perform efficiently for years. The downlights ... location listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment ...
(Date:8/14/2017)... ... August 14, 2017 , ... Every year, millions of ... the antibody community have recently come together to address this antibody crisis and ... , The team at Thermo Fisher Scientific has arranged ...
(Date:8/11/2017)... San Antonio, Texas (PRWEB) , ... August 11, 2017 , ... ... launching a rebranding campaign this month that will incorporate important key elements including a ... to thank the community that has supported them, Bill Miller has partnered with the ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... next week-- as students. From August 14th through the 16th, the University City ... debuted in the summer of 2016, provides Philadelphia-based middle school educators an opportunity ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):